TABLE 2 

Summary of pharmacokinetic parameters (geometric mean, confidence interval 95%) of verinurad in blood and plasma following a single oral dose of [14C]verinurad (10 mg, 500 μCi) given to healthy male subjects

AnalyteMatrixTmaxaCmaxAUC∞CL/FVss/Ft1/2CLr0–96 h
hng/mlng·h/mll/hlhml/min
Verinurad 
(N = 8)Plasma0.50
(0.50–0.75)160
(117–219)193
(152–246)51.8
(40.7–65.9)504
(368–690)14.8
(11.9–18.4)—
Urine——————11.5
(7.64–17.3)
Total radioactivityb (N = 8)Plasma0.50
(0.50–0.75)344
(255–465)906
(742–1110)——34.7
(26.9–44.7)—
Blood0.50
(0.25–0.75)190
(144–250)556
(428–723)——37.5
(19.9–70.6)—
Blood-to-plasma ratio—0.551
(0.527–0.576)0.614
(0.535–0.703)————
Plasma verinurad-to-total radioactivity—0.464
(0.433–0.496)0.213
(0.194–0.234)————

  • CL/F, oral clearance corrected by bioavailability F; t1/2, half-life; Vss/F, volume of distribution at equilibrium corrected by bioavailability F.

  • ↵a Tmax is expressed as median (range).

  • ↵b Cmax and AUC values expressed as nanogram equivalents/ml and nanogram equivalents · h/ml, respectively.